Researchers from Heidelberg University, Heidelberg University Hospital (Ukhd) and Heidelberg Institute for theoretical Studies (Hits) Have Developed A Synthetic Peeptide on the Natural Prottein Early Universal “Fuel” for Weakened Hearts.

The Researchers Combined Computer-Aided Methods With Lab Studies to Investigate the Therapeutic Effect of the so-called s100a1ct peptide molecule. The results have been Published in the journey Circulation,

The Protein S100A1 is Production in the Heart Muscle Cells and An Important Controller of Cardiac Function: It Regulates The Pumping Action of the Heart, Stabilizes The Heart Rhythm, ENSUSURES SOPPLECT Ively Protects Against Maladaptive Growth, For Example After A Heart Attack, That normally leads to heart muscle weakness and heart failure.

For a future therapeutic use of this protein, scientists from the heidelberg medical faculty and the faculties for engineering sciants and bioscience of heidelberg university developed a synheable Ombining Computer-Based Protein Modeling and Efficiency Studies on Heart Muscle Cells and Animals.

This Approach LED step by step to an optimized protein drug that could open up new treatment options for acute Cardiac insufficiency.

The Research Group LED by Dr. Julia Ritterhoff and Professor Dr. Patrick Most, Head of the Molecular and Translational Cardiology Section in the Department of Cardiology, Angiology and Pneumology at Ukhd, Has Been Studying the S100a1 Prottein for more.

The team has elucidated numerous functions of the protein in the cardiovascular system and based on this work, has already developed genes for methods for the treatment of chronic heart failure. These Approaches are now being prepared for Clinical Studies by a Start-Up Company Spun off from Heidelberg University and Ukhd.

Part of the natural protein as an active agent agent acute heart failure

Curiously, only a specific section of the protein seems to be responsible for the therapeutic Effects of S100A1 in Heart Muscle. “This molecular insight Gave Rise to the idea of ​​only using the putative active part of the s100a1 protein as a therapeutic agent.” Explains Dr. Ritterhoff.

This Short Protein Fragment, A So-Called Peptide, can be produced synthetically and directly applied intravenously as a drug with immediati the therapeutic efficacy. Such A Medicinal Concept With Precise Regulation of the heart’s contractil function via approves . In contrast, the Gene Therapy is Directed Against Chronic Heart Failure.

The development of this translational structure-based Drug Design Concept was only made poses Rebecca wade at hits and center of molecular biology of Heidelberg University (ZMBH). The approach was to integrate experiences on Heart Muscle Cells and Animals and Computational Molecular Modeling.

“Our lab developed a customized computer-aided modeling pipeline for this project to model the molecular structure of the poptide and interactions with the predicted molecular Effectors in the degree Eling guided the design of Specific Experiences to Investigate the Molecular Mechanisms. In this way, the strengths of computers-aided modeling and the expiral experience of the lab of Dr. Ritterhoff and Prof. Wade.

The poptide acts safely and therapeutically in Clinical Relevant Preclinical Models of Heart Fail

In their work, the two teams developed the basic structure of the new popt They used various preclinical molecular, cellular and animal models to demonstrate that the new peptide theraputic is safe and effective to reverent heart failure and that it ever AGAISTS AGAINST Lethal Arrthmi.

“The special thing about the molecular mechanism of s100A1C or acute decompensed heart failure treatment in Intensive Care, Temporarily Increase Cardiac output but can have Profound Negative Effects on the heart rhythm and Worsen the programs of our patients, “explains Prof. Most.

“We therefore consider the s100a1ct peptide to be a real advance and particularly suitable for intravenous administration in the event of an out of an out ITIS, for example. ” Before it can be used in the clinic, however, preclinical development and safety assessments from have to be carried out.

Provided by universitätsklinikum Heidelberg